17,261 trials
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 9.7; 12.6 months — p== 0.0106
Parkinson Disease
Primary: Number of Adverse Events — 27; 12 Number of Adverse Events
Bronchopulmonary Dysplasia
Primary: Combined Endpoint of Bronchopulmonary Dysplasia (BPD) or Mortality — 1; 2; 24; 25 Participants
Nausea · Vomiting · Cesarean Section
Primary: Pre-Induction Nausea Score — 0.067; 0 units on a scale
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Incidence of Grade III/IV GVHD — 2; 4 Participants
Contiguous Stage II Grade 1 Follicular Lymphoma · Contiguous Stage II Grade 2 Follicular Lymphoma · Contiguous Stage II Marginal Zone Lymphoma
Primary: Progression-free Survival — 92; 71; 83; 71 Kaplan-Meier estimated % of patients
B-cell Adult Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia · B-cell Chronic Lymphocytic Leukemia
Primary: Disease Relapse Rate — 18 Participants
HIV Infection
Primary: HPV-6 Antibody Level (Geometric Mean Titer of HPV-6) — 738.9 Milli-Merck units/milliliter (mMU/mL)
Raynaud Disease
Primary: Frequency of Vasospastic Attacks — 2.4; 2.0 attacks per day
Metastatic Breast Cancer · Breast Cancer · Progressive Breast Cancer
Primary: Central Nervous System (CNS) Objective Response Rate — 63 percentage of participants
Chronic Rhinosinusitis · Nasal Polyps
Primary: Objective (a) the Effect on Polypoid Mucosal Thickening in the Anterior Ethmoid and Maxillary Sinuses as Measured on Sinus CT Scan. — -8.9; 4.2 % Change
Metastatic Renal Cell Carcinoma
Primary: Objective Response in ISM Good Risk Group — .23 proportion of participants — p=0.042
Lung Cancer
Primary: Pathologically Complete Response — 0 percentage of participants
Immunodeficiency Syndrome · Non-Cancer Diagnosis
Primary: Number of Patients Who Achieve Greater Than 50% Donor T-cell Chimerism — 13 Participants
Trichotillomania · Hair Pulling
Primary: The National Institute of Mental Health Trichotillomania Symptom Severity Scale (NIMH-TSS) — 8.4; 8.4 units on a scale